A 25-year-old man presented with microangiopathic haemolytic anaemia and acute kidney injury. With a normal ADAMTS-13 level, negative faecal shigatoxin test and strong family history of atypical haemolytic uremic syndrome, he was commenced on eculizumab to good clinical response. Subsequent genetic testing revealed a heterozygous complement factor H mutation. Eculizumab was discontinued after 44 months of treatment, and he relapsed within 6 months, with the first sign being downtrending haptoglobin levels, with no other markers of haemolysis or thrombocytopaenia, 5 weeks prior to development of acute kidney injury. He was recommenced on eculizumab and to date still remains on it. This case highlights the unusual pattern of relapse and discusses the considerations for eculizumab discontinuation in patients with stable atypical haemolytic uremic syndrome receiving maintenance therapy.
INTRODUCTION
Haemolytic uremic syndrome (HUS) is a form of thrombotic microangiopathy (TMA) characterized by presence of microangiopathic haemolytic anaemia, thrombocytopenia and renal impairment. 1 It can be further sub-divided into infection related HUS, typically due to Shiga-toxin producing Escherichia coli infection, and atypical HUS resulting from a primary dysregulation of the complement alternative pathway. 2 Atypical HUS has an incidence of one per million per year and mainly affects children and young adults. 3 Mortality rate is up to 10% and at least a third progress to end stage kidney disease at the first episode. 4 Over the past few years, multiple mutations in genes encoding regulatory proteins of the complement alternative pathway have been identified, namely protein factor H (CFH, 20-30%), membrane cofactor protein (MCP, 5-15%), factor I (CFI, 4-10%), thrombomodulin (THBD, 3-5%), C3 convertase proteins, C3 (2-10%) and factor B (CFB, 1-4%). 4 Antibody against CFH is also found in 6-10% of cases, primarily children. 5 Identification of these mutations can help prognosticate and identify patients at high risk of disease relapse, progression to end stage renal failure and death. 4, 6 Eculizumab is a humanized monoclonal antibody to C5, which inhibits its cleavage to C5a and C5b and the subsequent formation of membrane attack complex (C5b-9). Multiple prospective clinical trials in patients with atypical HUS treated with eculizumab have demonstrated a significant improvement in renal function, haematological outcomes and quality of life. [7] [8] [9] However, the optimal duration of therapy and risk of relapse with eculizumab discontinuation remain largely unknown.
Here, we present a case of a 29-year-old male who experienced subclinical atypical HUS relapse a few months after cessation of eculizumab treatment. /L. The imaging of his renal tract was unrevealing, and he had microscopic haematuria but no significant proteinuria. His vasculitic screen was also unremarkable. Of note, he had normal C3 and C4 levels.
CASE REPORT
Given the clinical suspicion of thrombotic microangiopathy, he was started on plasmapheresis promptly. He subsequently underwent a renal biopsy which revealed endothelial swelling, thrombosis and fragmentation of red blood cells in the lumen of glomerular capillary and arterioles, confirming the aforementioned diagnosis. He had a normal ADAMTS-13 level of 69 % and was tested negative for faecal enterohaemorrhagic E. coli shiga-toxin genes. However, interestingly, his faecal test was positive for norovirus.
Further questioning revealed a strong family history of aHUS with a cousin on eculizumab infusion and another having lost a renal graft to the condition and was back on dialysis. Our patient was commenced on eculizumab infusion the same week after being vaccinated against meningococcus, and had a good response. He only needed two sessions of haemodialysis, and his haemolysis markers normalized within three weeks. Plasmapheresis continued until commencement of eculizumab. Genetic testing for aHUS was performed and detected a heterozygous CFH:c.3643C>G variant located in the C-terminal portion of factor H within a region important for C3b binding.
In the ensuing 6 months, he also developed malignant hypertension requiring three antihypertensive agents, namely Labetolol 200 mg two to three times daily, Lercanidipine 20 mg daily and Ramipril 5 mg daily. In fact, he tried to cease his antihypertensives 3 months after the diagnosis of atypical HUS, and this resulted in seizures. He has never stopped his antihypertensives since, and his blood pressure has been well controlled subsequently.
He remained on fortnightly eculizumab 1200 mg for the following 44 months. His serum creatinine settled to a new baseline of 120 umol/L with no laboratory evidence of haemolysis throughout that period. Due to no further compassionate access and his 12-month supply of eculizumab under the Australian Pharmaceutical Benefits Scheme running out, adding to the fact that his condition had been very well controlled, a decision was made to try him off eculizumab.
Fourteen weeks following cessation of eculizumab, his serum haptoglobin began to downtrend. He stayed under close observation and within 6 weeks, haptoglobin fell significantly from 0.33 to 0.12 g/L. His creatinine rose to 144 nmol/L. His platelet and LDH remained unaffected, and blood film did not have any red blood cell fragments. He also did not have significant haematuria or proteinuria. Two weeks later, his creatinine rose further to 195 and haptoglobin became undetectable (<0.06), still without other overt evidence of microangiopathic haemolytic anaemia. His platelet count remained in the normal range of 157 × 10 9 /L, but there was a 25% decrease in total platelet count compared with the reading of 207 × 10 9 /L three weeks prior. He was relatively asymptomatic throughout this period apart from chronic headaches, lethargy and mild nausea. Figures 1 and 2 show the trends of his serum creatinine, haptoglobin, platelet count and LDH following eculizumab cessation.
A relapse of aHUS was strongly suspected at this point, and he was started on plasmapheresis. Re-application for eculizumab was also done urgently. He had a total of four sessions of plasmapheresis before recommencing on eculizumab at the previous maintenance dose of 1200 mg fortnightly. Within 4 weeks of restarting eculizumab, his renal function improved with serum creatinine falling to 131 nmol/L and haptoglobin normalized. He now continues on eculizumab infusion indefinitely.
DISCUSSION
Our patient has a predisposition to complement dysregulation with a CFH mutation. An episode of viral gastroenteritis appeared to have triggered his initial episode and he responded well to C5 blockade with eculizumab. A paediatric study done in the pre-eculizumab era reported that CFH mutation was associated with poorer renal and mortality outcomes, with 60% reaching end stage kidney disease or dead within the first year, compared with factor I and membrane cofactor protein mutation. 10 The decision to discontinue eculizumab treatment in an individual with a high risk genetic mutation is controversial. The literature on discontinuation of eculizumab for aHUS is scant. Risks of relapse appear to vary with different underlying mutations. Ardissino et al. reported a case series of 16 patients who elected to discontinue therapy after achieving clinical remission. Possible benefits for discontinuation included reduction in risk of meningococcal infection, prevention of development of immune-mediated drug reaction, better quality of life with less frequent attendance to healthcare facilities, and reduction in treatment cost. Five of them relapsed within six months in the form of worsening renal function but improved rapidly upon recommencement of eculizumab. Four out of five of them had a CFH mutation. 11, 12 Carr and Cataland Fig. 1 Trends of serum creatinine and haptoglobin following eculizumab discontinuation.
aHUS relapse post eculizumab cessation also described a case of a young female with CFH mutation who relapsed after 6 months with acute kidney injury, and features of florid TMA. 13 However, in subsequent case series published by Wetzels and van de Kar, only one out of three patients with CFH mutation relapsed after ceasing eculizumab treatment, raising the possibility that CFH mutations in different exons may have different course of disease. 14 We recommend that all patients with atypical HUS undergo genetic testing, and if a high risk mutation is identified, caution should be exercised when ceasing eculizumab treatment. We would also like to highlight the unusual pattern our patient relapsing. For five weeks, the only abnormality was a decreasing haptoglobin. Without a decreasing platelet count or evidence of TMA-related organ damage, he did not meet criteria for recommencement of eculizumab under the Australian Pharmaceutical Benefits Scheme. 15 Had treatment been delayed any further, he could have suffered from irreversible renal injury. We urge that the criteria for recommencement of eculizumab be reviewed so that patients with an established history of atypical HUS at high risk of relapse can access this medication at the first suggestion of relapse, without having to wait till development of organ failure or full blown thrombotic microangiopathy.
CONCLUSION
Atypical haemolytic uremic syndrome is a rare condition with catastrophic clinical outcomes if left untreated. Complement alternative pathway inhibition with eculizumab has proven efficacy in this condition. Certain genetic mutations appear to confer a higher risk of relapse. Eculizumab treatment may be able to be withdrawn safely in some patients, even the high risk ones, but they need to be followed up closely and be restarted on eculizumab if a relapse is suspected.
